Moneycontrol PRO
HomeNewsBusinessMarketsLupin shares gain on USFDA approval for Loteprednol Etabonate Ophthalmic gel

Lupin shares gain on USFDA approval for Loteprednol Etabonate Ophthalmic gel

Lupin Share Price | Loteprednol Etabonate Ophthalmic Gel is bioequivalent to Lotemax SM Ophthalmic Gel of Bausch & Lomb Inc and will be manufactured at Pithampur facility in India.

July 02, 2025 / 09:24 IST
Lupin Share Price Today
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Lupin share price gained in the early trade on July 2 on the back of USFDA approval for Loteprednol Etabonate Ophthalmic Gel.

    At 09:20am, Lupin was quoting at Rs 1,969.70, up Rs 8.40, or 0.43 percent, on the BSE.

    " ...... has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application for Loteprednol Etabonate Ophthalmic Gel, 0.38%," company said in the exchange filing.

    Loteprednol Etabonate Ophthalmic Gel is bioequivalent to Lotemax SM Ophthalmic Gel of Bausch & Lomb Inc.

    The company is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity, which will be manufactured at Pithampur facility in India.

    The gel is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery.

    Catch all the market action on our live blog

    Also, company announced the strategic carve-out of its consumer healthcare business, LupinLife Consumer Healthcare Ltd. (LCH), into a wholly owned subsidiary, effective July 1, 2025, with the aspiration to establish a specialized consumer healthcare entity, with an enhanced focus on India's rapidly growing selfcare market.

    In June, the company launched Prucalopride Tablets, 1 mg, and 2 mg, in the United States, following the approval from the USFDA.

    Also, the company has entered into a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for the commercialization of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule. This strategic collaboration aims to address the treatment of chronic obstructive pulmonary disease (COPD) in China, a market with a growing need for advanced respiratory care solutions.

    The share touched a 52-week high of Rs 2,403.45 and a 52-week low of Rs 1,626.45 on 02 January, 2025 and 03 July, 2024, respectively.

    Currently, the stock is trading 18.05 percent below its 52-week high and 21.1 percent above its 52-week low.

    The market capitalisation of the company stands at Rs 89,959.37 crore.

    Moneycontrol News
    first published: Jul 2, 2025 07:32 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347